alt

53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013)

September 10-13, 2013, Denver

Back Home Content Conference Coverage

ICAAC 2013: Dolutegravir Shows Good Efficacy Across Patient Groups

The new integrase inhibitor dolutegravir (Tivicay) worked better than boosted darunavir for people starting HIV treatment for the first time, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) last week in Denver. Another study found that dolutegravir worked well across sex, race/ethnicity, and age groups.

alt

Read more:

ICAAC 2013: Researchers Present Data on New NNRTIs AIC292 and MK-1439

A pair of next-generation HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) demonstrated promising activity in early studies, researchers reported last week at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver. AIC292 showed good antiviral activity in early laboratory, animal and human studies. MK-1439, now in Phase 2b, is likely to interact with ritonavir, but not tenofovir.

alt

Read more:

ICAAC 2013: CD4 Cell Gene Therapy May Enable Functional Control of HIV Off Treatment

Two people whose CD4 T-cells were modified to make them resistant to HIV experienced substantial CD4 cell gains and were able to maintain viral suppression after interruption of antiretroviral therapy (ART), according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.

alt

Read more:

ICAAC 2013: New Tenofovir Formulation Has Less Effect on Kidneys and Bones

Tenofovir alafenamide (TAF), a new formulation that reaches higher levels in cells but allows for lower dosing, was as effective as the current tenofovir disoproxil fumarate (TDF) formulation but had less impact on markers of kidney function and bone turnover, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this week in Denver.

alt

Read more:

ICAAC 2013: Tenofovir Vaginal Ring Protects Monkeys on Depo-Provera Against HIV-like Virus

An intravaginal ring containing tenofovir protected all but 1 macaque monkey given hormonal contraceptives and repeatedly exposed to a hybrid human/simian virus similar to HIV, according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver.

alt

Read more: